Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patientSarita D Boyd, Frank Maldarelli, Irini Sereti, G Laissa Ouedraogo, Catherine A Rehm, Valerie Boltz, Diana Shoemaker, Alice K Pau
Corresponding author name: Sarita D Boyd
Corresponding author e-mail: email@example.com
Citation: Antiviral Therapy 2011; 16:257-261
Date published online: 04 March 2011
Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.